LATEST NEWS

Mar-16-2017

Protalix BioTherapeutics Reports 2016 Full Year Results and Provides Corporate Update

Current Cash is projected to Fund the Company through Three Clinical Trial Read-Outs and into 2019 CARMIEL, Israel, March 16, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced its financial results for the full-year ended December 31, 2016, and provided... 
Mar-09-2017

Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017

CARMIEL, Israel, March 09, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report full-year 2016 financial results and provide a corporate update on Thursday, March 16, 2017 at 8:30 am ET. To participate in the conference call, please d... 
Feb-14-2017

Protalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders

CARMIEL, Israel, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that its board of directors approved the record date for the Company’s 2017 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on or about April 10, 2017.  Holders of the Company’s common stock at the close of business on March 15, 2017, the record date, will be entitled to receive notice of, and to vote at, the Annual Meeting. About Protalix BioTherapeu... 
All News